Image

Saving Organs.
Saving Lives.

Transplant Surgeons
OPOs
Image

Latest Updates

The U.S. FDA has just granted VPS a Breakthrough Device Designation for the VP.S Encore™ device.

“We are thrilled with this designation. We can now interact more efficiently and quickly with the FDA as we work to bring this lifesaving technology to patients everywhere.” – Leonid Bunegin, VPS Chief Scientific Officer
See the full press release
San Antonio Express News:
New Invention by San Antonio Scientist Could Be a ‘Game Changer’ in Lifesaving Heart Transplants
Read the Article

VP.S Encore™ (previously the ULiSSES™device) Wins Create the Future Grand Prize

Out of 700 entries from 60 countries, VPS’s innovative device takes design award.

Let’s change the organ transplant world.

By doubling the viability of organs from 4 hours to 8 hours, more organs will be available for transplant, and more lives will be saved.

Why 8 hours is transformational

Extending the life of organs outside of the body from four hours (the time a heart remains viable, for example) to 8 hours will profoundly transform the world of organ preservation, resuscitation, and transport.
Image
Image
Image

Unparalleled Portability with

Image
The VP.S Encore™ device, which is about the size of a small coffee carafe and fits into the overhead bin of any commercial airliner. This allows VP.S Encore™ to efficiently transport organs worldwide, and thus dominate the preservation, resuscitation, and transport market.
Image
By comparison, competing technologies that utilize blood to help keep organs alive are significantly larger—the size of a large office copier machine—presenting transportation and storage challenges that can limit efficiency and use.

Unparalleled Affordability with

Image

The VP.S Encore™ is a one-time use device with patented technology that perfuses organs and vascularized tissues with oxygen. The entire VP.S Encore™ device costs less than the replacement cartridge of a top competitor.

Unparalleled Ease of Use with

Image
The VP.S Encore™ is a one-time use, disposable device that operates with a preservation solution that is readily available in any hospital, emergency room, clinic or emergency transport unit. It is designed to operate at any room temperature, and at any cabin pressure during flights.
Image

VP.S Encore™ is a game-changer.

The very first organ ever transplanted was placed in a cooler and packed in ice, and that is still how most organs are preserved 65 years later. This is unacceptable. Vascular Perfusion Solutions (VPS®) is working with a team of world-class scientists to perfect VP.S Encore™, a device designed to perfuse and resuscitate tissue, allowing organs  to remain viable for more than 8 hours.

Click here for more details on our efforts.

Our next round of research

VP.S Encore™ has already been successfully tested in small animal studies, and these studies are ongoing. Human testing will follow. These steps are important if we are to finally change the world of organ transplantation.

Ask a Question

Our team is here to help by providing information regarding organ and tissue transportation, as well as related information in the field of long-term organ and tissue preservation, for medical use and transplant. Please contact us at info@vascularperfusion.solutions, or submit a question using the form below.

Literature

Here you can read about some of our early investigation and technology development.
Preserving Limbs in 21st Century

For those that are interested in learning more about the state of the art in machine perfusion for kidneys, the following article is available:
Machine perfusion preservation versus static cold storage for deceased donor kidney transplantation - Tingle, SJ - 2019 | Cochrane Library

This paper, authored by the inventor of VP.S ENCORE™, illustrates the advantages of oxygenated perfusion. We are excited to note that the VP.S technology is quite different from what is illustrated in this paper. It is much more efficient, and represents a dramatic improvement in the ability of the device to keep organs and limbs alive. Patent applications are pending.
Novel portable hypothermic pulsatile perfusion preservation technology: Improved viability and function of rodent and canine kidneys